Applying Precision Medicine in BRAF V600E-Mutant Metastatic Colorectal Cancer: Aparna Parikh, MD, MS, and Theresa Gillespie, PhD, MA, RN, FAAN

Oncology Data Advisor™ · Applying Precision Medicine in BRAF V600E-Mutant Metastatic Colorectal Cancer Colorectal cancer is the second leading cause of cancer death among men and women in the United States (ACS,2021). An estimated 149,500 new cases are diagnosed annually, and 52,980 people die of the disease (ACS, 2021). When detected and treated early at a localized stage, the 5-year survival rate is 90%. However, because colorectal cancer initially exhibits no symptoms and the use...
Continue reading

Can Metabolic Regulators Fight Metastatic Melanoma?

Vemurafenib, an inhibitor of mitogen-activated protein kinase signaling downstream of BRAFV600E, can be successfully used to treat patients with metastatic melanoma. However, it produces a high incidence of therapeutic resistance. New strategies are needed to treat vemurafenib-resistant melanoma, so researchers used two bioactive compound libraries and identified two possible targets: deguelin and rotenone. "Breakthroughs in understanding the molecular basis for the disease have led to a couple ...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.